C-WZUKMSC-derived extracellular vesicles, cell-free therapy, regenerative medicine
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Aegle Therapeutics states that it is developing novel regenerative medicine therapeutics based on a proprietary microvesicle isolation technology, with a focus on treating burns, chronic wounds, orthopedic injury, cardiovascular disease, and certain rare diseases. The company presents microvesicle therapy as a scalable, low-cost therapeutic approach derived from adult human stem cells and aimed at addressing substantial unmet medical needs.
SourceAegle Therapeutics stated that it was a development-stage company focused on commercializing landmark research from the Miller School of Medicine at the University of Miami, indicating a belief in advancing university-originated biomedical research toward practical therapeutic use.
SourceAegle Therapeutics stated that its proprietary extracellular vesicle isolation technology could harness the healing power of mesenchymal stem cells without the risks of cell proliferation or engraftment, while also being scalable and low cost. The company presented this approach as the basis for regenerative healing therapies, especially for burns, epidermolysis bullosa, chronic wounds, and related indications.
SourceAegle Therapeutics presents the view that extracellular vesicles derived from adult human stem cells can serve as therapeutic agents in regenerative medicine. The company states that these vesicles are the paracrine wound-healing mediators of stem cells, and that its proprietary isolation technology can recover therapeutic-grade vesicles without structural or functional damage in a scalable, low-cost process for treating burns, chronic wounds, orthopedic injury, cardiovascular disease, and certain rare diseases.
SourceAegle Therapeutics Corporation presents itself as a development-stage company commercializing University of Miami research and states that difficult-to-heal wounds are a growing problem. The company says its patent-pending stem cell and laser technology stimulates the body's natural healing responses, leading to improved healing and reduced scarring.
SourceAegle Therapeutics Corporation stated that chronic or recalcitrant wound healing is a growing problem and that its patent-pending stem cell and laser technology can stimulate the body's natural healing responses, leading to improved healing and reduced scarring.
Source